JC06 Rec CT/PTO 18 MAY 2005

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ction of information unless it displays a valid OMB control number Under th 1995, no persons are required to respond to a c Application Number 10/520,863 TRANSMITTAL Filing Date January 11, 2005 First Named Inventor **FORM** Shue, Youe-Kong Art Unit **Examiner Name** (to be used for all correspondence after initial filing) Attorney Docket Number 8024-005-US Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Change of Correspondence Address Status Letter Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Journal References Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Catalyst Law Group, APC Signature Printed name Laura Pereira, Esq. Date Reg. No. May 16, 2005 55.534 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with

sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

Date

May 16, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Typed or printed name

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Examiner: TBD
)	
Optimer Pharmaceuticals, Inc.)	Group Art Unit: TBD
)	
Serial No.: 10/520,863	•	Docket No.: 8024-005-US
)	
Filed: January 11, 2005)	Date Mailed: May 16, 2005
)	
For: TIACUMICIN PRODUCTION)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir or Madam:

This document is an Information Disclosure Statement to the above-cited patent application.

Attached is at least one form PTO/SB/08A/B listing documents believed relevant to the subject application. The submission of the following information is not intended, nor should it be construed, to constitute an admission that any patent, article, or other

information referred to herein is "prior art" unless specifically designated as such. In accordance with 37 C.F.R. § 1.97(b), the filing of this information shall not be construed to mean that a search has been made or that no other material information may exist. Neither should its submission be construed to indicate that a thorough search should not be conducted by the Examiner.

It is believed that this disclosure complies with the requirements of 37 C.F.R. § 1.96, § 1.97, and § 1.98 and the Manual of Patent Examining Procedures § 707.05(b). If for some reason the Examiner considers otherwise, it is respectfully requested that the undersigned be telephoned at (858) 450-0099 x304 so that any deficiencies can be remedied.

It is believed that this Information Disclosure Statement is being submitted before the mailing of an Office Action on the merits. Accordingly, no fee is believed to be due under 37 C.F.R. § 1.97(b)(3). If an Office Action on the merits has in fact been mailed, authorization is hereby given to charge the required fee of \$180.00 under 37 C.F.R. § 1.97(c)(2) and § 1.17(p) to Deposit Account No. 502-235.

A copy of each journal document is enclosed. Some of the journal documents may have markings thereon. No significance is to be attached to the markings. These documents are not necessarily analogous art. Additionally, the order of the following documents is to be accorded no particular import, as the order thereof is completely fortuitous.

It is respectfully requested that these documents be: (1) fully considered by the Patent and Trademark Office during the prosecution of this application; and (2) represented on any patent which may issue on the application. Applicant respectfully requests that copies of the forms PTO/SB/08A/B, as considered and initialed by the Examiner, be returned with the next communication.

1. U.S. Patent No. 4.918,174, issued on April 17, 1990 to applicants McAlpine, et al.;

- 2. A publication, Theriault, Robert J., et al., "Tiacumicins, A Novel Complex of 18-Membered Macrolide Antibiotics" J. Antibiotics, Vol. XL, 5, pgs. 567-574, 1987.
- 3. A publication, Demain et al. "Manual of Industrial Microbiology and Biotechnology", American Society for Microbiology, Washington D.C., 1986, pgs. 123-126.

If any issues remain, the Examiner is respectfully requested to telephone the undersigned at (858) 450-0099.

Respectfully submitted,

Date: May 16, 2005

Laura Pereira, Esq. Registration 55,534

CATALYST LAW GROUP, APC 4220 La Jolla Village Drive, Suite 220 San Diego, CA 92122

Phone: (858) 450-0099 Fax: (858) 450-9834



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/520,863 Filing Date January 11, 2005 INFORMATION DISCLOSURE First Named Inventor Shue, Youe-Kong STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) **Examiner Name** Sheet 1 Attorney Docket Number 8024-005-US of 2

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages Columns Lines Where	
Initials*	No.1	Number-Kind Code ^{2 (f known)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		^{US-} 4,918,174	04-17-1990	McAlpine, et al.		
		US-				
		US-				
		UŞ-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

		FOREI	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	f known) MM-DD-YYYY		Or Relevant Figures Appear	T ⁶

Examiner	Date	, and the second	
Signature	Considered		
-			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known				
V				Application Number	10/520,863	
INF	ORMATION	DIS	CLOSURE	Filing Date	January 11, 2005	
STA	STATEMENT BY APPLICANT			First Named Inventor	Shue, Youe-Kong	
				Art Unit		
(Use as many sheets as necessary)			lecessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	8024-005-US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Demain et al. "Manual of Industrial Microbiology and Biotechnology", American Society for Microbiology, Washington D.C., 1986, pgs. 123-126.	
		Theriault, Robert J., et al., "Tiacumicins, A Novel Complex of 18-Membered Macrolide Antibiotics" J. Antibiotics, Vol. XL, 5, pgs. 567-574, 1987.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.